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Previous epidemiologic studies have indicated
that exposure to ambient particulate matter
(PM) is linked to increases in mortality and
morbidity related to respiratory diseases
(Abbey et al. 1999; Cohen and Pope 1995).
The concentration of PM of mass median
aerodynamic diameter (a density-dependent
unit of measure used to describe the diameter
of the particle) of ≤ 10 µm (PM10) is related to
daily hospital admissions for asthma, acute and
chronic bronchiolitis, and lower respiratory
tract infections (Dockery and Pope 1994),
whereas the concentration of PM ≤ 2.5 µm in
mass median aerodynamic diameter (PM2.5) is
more closely associated with both acute and
chronic respiratory effects and subsequent
mortality (Peters et al. 1997). Among a variety
of constituents involved in PM2.5, diesel
exhaust particles (DEPs), which are small par-
ticles with carbonaceous cores (Schuetzle
1983), are important for their apparent toxic-
ity (Morgan et al. 1997; Pandya et al. 2002).
We and others have demonstrated that DEPs
have respiratory toxicity with or without pre-
disposing factors in vivo (Ichinose et al. 1995,
1997; Takano et al. 1997, 2002).
To date, nanoparticles (particles < 0.1 µm
in mass median aerodynamic diameter) have
been postulated to affect cardiopulmonary sys-
tems (Nel 2005; Peters et al. 1997; Utell and
Frampton 2000). Nanoparticles are reportedly
able to penetrate deeply into the respiratory
tract and have a larger surface area per unit
mass than do larger particles, thus resulting in
a greater inﬂammatory response (MacNee and
Donaldson 2000; Nemmar et al. 2001).
Indeed, two in vivo studies have demonstrated
that nanoparticles have marked pulmonary
toxicity compared with larger particles (Ferin
et al. 1992; Li et al. 1999). Recently, we have
demonstrated that carbon nanoparticles can
aggravate antigen-related airway inﬂammation
(Inoue et al. 2005a). The enhancing effects are
more prominent with 14-nm nanoparticles
than with larger particles (56 nm) in overall
trend (Inoue et al. 2005a). On the other hand,
we have previously demonstrated that DEPs
(8 mg/kg; Takano et al. 2002) and DEP-
derived components (4 mg/kg; Yanagisawa
et al. 2003) aggravate lung inflammation
related to bacterial endotoxin [lipopolysaccha-
ride (LPS)]. However, effects of nanoparticles,
in particular their size effects, on pulmonary
inflammatory conditions related to bacterial
endotoxin have not been fully investigated.
Furthermore, nanoparticles can translocate
from the lung into the circulation (Nemmar
et al. 2002a, 2002b, 2003), raising the possi-
bility that nanoparticles may facilitate not
only lung inflammation but also hemostatic
disturbance in the circulation.
The present study was designed to eluci-
date the effects of two sizes of carbon black
nanoparticles (14 nm or 56 nm) on lung
inflammation induced by intratracheal
administration of bacterial endotoxin. We
also investigated the local expression of
cytokines, chemokines, and 8-hydroxyguano-
sine (8-OHdG) in the lung. Finally, we
examined the effects of airway exposure to
nanoparticles on coagulatory changes.
Materials and Methods
Animals. We used ICR male mice, 6 weeks of
age, weighing 29–33 g (Japan Clea Co.,
Tokyo, Japan). This strain has been reported
to be highly responsive to LPS compared with
Balb/c, C3H/He, or A/J mice (Haranaka et al.
1984) in all experiments. These mice were fed
a commercial diet (Japan Clea Co.) and given
water ad libitum. Mice were housed in an ani-
mal facility that was maintained at 24–26°C
with 55–75% humidity and a 12/12-hr
light/dark cycle.
Study protocol. Mice were divided into six
experimental groups. The vehicle group
received phosphate-buffered saline, pH 7.4
(Nissui Pharmaceutical Co., Tokyo, Japan)
containing 0.05% Tween 80 (Nakalai Tesque,
Kyoto, Japan). The LPS group received
2.5 mg/kg LPS (Sigma Chemical, St. Louis,
MO, USA) dissolved in vehicle. Each
nanoparticle group received 4 mg/kg carbon
black nanoparticles (14 nm, PrinteX 90;
56 nm, PrinteX 25; Degussa, Dusseldorf,
Germany) suspended in vehicle. The LPS plus
nanoparticle groups received LPS (2.5 mg/kg)
combined with nanoparticles (4 mg/kg) in
vehicle. The surface areas of 14-nm nanoparti-
cles and 56-nm nanoparticles are 300 m2/g
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BACKGROUND: Although adverse health effects of particulate matter with a diameter of < 100 nm
(nanoparticles) have been proposed, molecular and/or experimental evidence for their facilitation of
lung inﬂammation in vivo is not fully deﬁned.
OBJECTIVE: In the present study we investigated the effects of nanoparticles on lung inﬂammation
related to bacterial endotoxin [lipopolysaccharide (LPS)] in mice.
RESULTS: We intratracheally administered vehicle, two sizes (14 nm, 56 nm) of carbon black
nanoparticles (4 mg/kg), LPS (2.5 mg/kg), or LPS plus nanoparticles and evaluated parameters for
lung inﬂammation and coagulation. Nanoparticles alone induced slight lung inﬂammation and sig-
niﬁcant pulmonary edema compared with vehicle. Fourteen-nanometer nanoparticles intensively
aggravated LPS-elicited lung inﬂammation and pulmonary edema that was concomitant with the
enhanced lung expression of interleukin-1β (IL-1β), macrophage inflammatory protein-1α
(MIP-1α), macrophage chemoattractant protein-1, MIP-2, and keratinocyte chemoattractant in
overall trend, whereas 56-nm nanoparticles did not show apparent effects. Immunoreactivity for
8-hydroxyguanosine, a marker for oxidative stress, was more intense in the lungs from the
LPS + 14-nm nanoparticle group than in those from the LPS group. Circulatory ﬁbrinogen levels
were higher in the LPS + plus 14-nm nanoparticle group than in the LPS group.
CONCLUSIONS: Taken together, evidence indicates that nanoparticles can aggravate lung inﬂamma-
tion related to bacterial endotoxin, which is more prominent with smaller particles. The enhance-
ment may be mediated, at least partly, via the increased local expression of proinflammatory
cytokines and via the oxidative stress. Furthermore, nanoparticles can promote coagulatory distur-
bance accompanied by lung inﬂammation.
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Perspect 114:1325–1330 (2006). doi:10.1289/ehp.8903 available via http://dx.doi.org/ [Online
12 June 2006]and 45 m2/g, respectively (disclosed by
Degussa). Nanoparticles were autoclaved at
250°C for 2 hr before use. The LPS activity,
which was determined by Limulus amebocyte
lysate assay (Seikagaku-kogyo, Tokyo, Japan),
was lower than the detection limit (0.001
endotoxin units per milliliter) in the nano-
particles after treatment. The suspension was
sonicated for 3 min using an ultrasonic dis-
rupter (model UD-201; Tomy Seiko, Tokyo,
Japan). In each group, vehicle, LPS, nano-
particles, or LPS plus nanoparticles were dis-
solved in 0.1 mL aliquots and mice were
inoculated once by the intratracheal route
through a polyethylene tube under anesthesia
with 4% halothane (Hoechst Japan, Tokyo,
Japan), as previously described (Ichinose et al.
1998; Takano et al. 1997). The animals were
deeply anesthetized, studied, and then sacri-
ﬁced 24 hr after intratracheal administration.
The studies adhered to the U.S. National
Institutes of Health guidelines for the experi-
mental use of animals (Institute of Laboratory
Animal Resources 1996). All animal studies
were approved by the institutional review
board of the National Institute for Environ-
mental Studies. The animals were treated
humanely and with regard for alleviation of
suffering.
Bronchoalveolar lavage. Bronchoalveolar
lavage (BAL) and cell counts in BAL fluid
(n = 7–8 in each group) were conducted as pre-
viously reported (Takano et al. 1997). In brief,
the trachea was cannulated after the collection
of blood. The lungs were lavaged with 1.2 mL
sterile saline at 37°C instilled bilaterally by
syringe. The lavaged fluid was harvested by
gentle aspiration. This procedure was con-
ducted two more times. Average volume
retrieved was > 90% of the 3.6 mL that was
instilled; the amounts did not differ among
treatments. The fluid collections were com-
bined and cooled to 4°C. The lavaged fluid
was centrifuged at 300 × g for 10 min, and the
total cell count was determined on a fresh ﬂuid
specimen using a hemocytometer. Differential
cell counts were assessed on cytologic prepara-
tions. Slides were prepared using an Autosmear
(Sakura Seiki Co., Tokyo, Japan) and were
stained with Diff-Quik (International Reagents
Co., Kobe, Japan). A total of 500 cells were
counted under oil-immersion microscopy.
After BAL procedure, the lungs were removed,
snap-frozen in liquid nitrogen, and stored at
–80°C for enzyme-linked immunosorbent
assays (ELISAs).
Lung water content. In another experi-
ment, after the collection of blood, the bilateral
lungs were weighed immediately after exsan-
guination and dried in an oven at 95°C for
48 hr. Thereafter, lung water content was esti-
mated by calculating the ratio of lung weight
[wet weight – dry weight (in milligrams)] to
body weight (in grams), with eight animals per
group (Ichinose et al. 1995).
Histologic evaluation. In a separate
experiment, after exsanguination, the lungs
were fixed by intratracheal instillation of
10% neutral phosphate-buffered formalin at
a pressure of 20 cm H2O for at least 72 hr.
Slices 2–3 mm thick of all pulmonary lobes
were embedded in paraffin. Sections (3 µm
thick) were stained with hematoxylin and
eosin (H&E) or were subjected to immuno-
histochemistry. Neutrophil infiltration was
expressed as the number of neutrophils per
high-power field (HPF) by counting the
number of neutrophils in > 30 fields at a
magniﬁcation of 100× in each slide (n =5  i n
each group). Histologic sections were evalu-
ated in a blind fashion.
Measurement of cytokines and chemokines
in lung tissue supernatants. Frozen lungs were
subsequently homogenized with 10 mM
potassium phosphate buffer (pH 7.4) contain-
ing 0.1 mM EDTA (Sigma), 0.1 mM phenyl-
methanesulfonyl fluoride (Nacalai Tesque,
Kyoto, Japan), 1 µM pepstatin A (Peptide
Institute, Osaka, Japan), and 2 µM leupeptin
(Peptide Institute) as described previously
(Takano et al. 1997). The homogenates were
then centrifuged at 105,000 × g for 1 hr. The
supernatants were stored at –80°C. ELISAs
for tumor necrosis factor-α (TNF-α), inter-
leukin-1β (IL-1β; Endogen, Cambridge, MA,
USA), macrophage inﬂammatory protein-1α
(MIP-1α; R&D Systems, Minneapolis, MN,
USA), MIP-2 (R&D Systems), macrophage
chemoattractant protein-1 (MCP-1; R&D
Systems), and keratinocyte chemoattractant
(KC; R&D Systems) in lung tissue super-
natants were conducted according to the
manufacture’s instruction (n = 7–8 in each
group).
Immunohistochemistry. The production of
oxidative-stress–related molecules in the lung
was detected by the immunohistochemical
analysis using anti–8-OHdG polyclonal anti-
body (Japan Institute for the Control of
Aging, Shizuoka, Japan; n = 5 in each group)
using the HistoMouse-Plus kit (Zymed
Laboratories, San Francisco, CA, USA). For
each lung specimen, the extent and intensity
of positive staining were graded on a scale of
0–4+ by two blinded observers on two sepa-
rate occasions using coded slides as previously
described (Sano et al. 1992).
Coagulation analysis. In another experi-
ment, after deep anesthesia, the chest and
abdominal walls were opened, blood was
retrieved from each mouse by cardiac punc-
ture, collected into 3.8% sodium citrate in a
ratio of 10:1, and centrifuged at 2,500 × g for
10 min. We measured prothrombin time (PT),
activated partial thromboplastin time (APTT),
fibrinogen, activated protein C (APC), and
activity for von Willebrand factor (vWF)
(n = 14–16 in each group) using a commercial
kit (Diagnostica Stago, Roche, Tokyo, Japan)
and an STA Compact analyzer (Diagnostica
Stago, Roche) as previously described (Inoue
et al. 2004).
Statistical analysis. All data were con-
firmed to be normally distributed by the
Kolmogorov-Smirnov test. Data are reported
as mean ± SE. We determined differences
between groups using analysis of variance
(ANOVA; StatView, version 4.0; Abacus
Concepts Inc., Berkeley, CA, USA). If differ-
ences between groups were significant
(p < 0.05) using one-way ANOVA, Bonferoni
correction was used for multiple comparisons.
Results
Effects of nanoparticles on airway inﬂamma-
tion and pulmonary edema. To estimate the
magnitude of airway inﬂammation, we exam-
ined the cellular profile of BAL fluid 24 hr
after intratracheal instillation (Table 1).
Nanoparticles alone increased the numbers of
total cells and neutrophils compared with vehi-
cle, but they did not reach statistical signifi-
cance. LPS exposure signiﬁcantly increased the
numbers compared with vehicle exposure
(p < 0.01). The numbers were significantly
greater in the LPS + 14-nm nanoparticle group
than in the LPS group or the 14-nm nanopar-
ticle group (p < 0.01). The numbers were
greater also in the LPS + 56-nm nanoparticle
group than in the 56-nm nanoparticle group
(p < 0.01). Next, to estimate pulmonary
edema, we examined lung water content 24 hr
after intratracheal instillation (Table 1). Airway
exposure to nanoparticles or LPS signiﬁcantly
enhanced the pulmonary edema compared
with vehicle exposure (p < 0.05 for 14-nm
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Table 1. Total cells and neutrophils in BAL fluid and lung water content (mean ± SE) after intratracheal
challenge.
Cells (× 104/total BAL ﬂuid) Lung weight to
Treatment Total cells Neutrophils body weight ratioa
Vehicle 61.8 ± 4.7 13.9 ± 7.2 5.19 ± 0.08
14-nm nanoparticles 180.9 ± 35.8 146.6 ± 33.6 5.95 ± 0.08*
56-nm nanoparticles 222.3 ± 21.6 132.8 ± 19.1 6.73 ± 0.33**
LPS 770.9 ± 49.7** 711.6 ± 50.3** 9.01 ± 0.16**
LPS + 14-nm nanoparticles 1236.1 ± 145.7**,##,†† 1134.6 ± 135.0**,##,†† 9.93 ± 0.30**,#,††
LPS + 56-nm nanoparticles 826.2 ± 90.2**,†† 750.6 ± 80.8**,†† 9.40 ± 0.21**,††
a(Wet weight – dry weight)/body weight. *p < 0.05 versus the vehicle group. **p < 0.01 versus the vehicle group. #p < 0.05
versus the LPS group. ##p < 0.01 versus the LPS group. ††p < 0.01 versus the nanoparticle group.nanoparticles, p < 0.01 for 56-nm nano-
particles or LPS). The value was signiﬁcantly
greater in the LPS + 14-nm nanoparticle group
than in the LPS group (p < 0.05) or the 14-nm
nanoparticle group (p < 0.01). The value was
also greater in the LPS + 56-nm nanoparticle
group than in the 56-nm nanoparticle group
(p < 0.01).
Effects of nanoparticles on histologic
changes in the lung. To determine the effects
of nanoparticles on lung histology, we evalu-
ated lung specimens stained with H&E 24 hr
after intratracheal instillation (Figure 1). No
pathologic changes were seen in the lung
obtained from the vehicle group (Figure 1A).
We observed slight inﬁltration of neutrophils
in the lungs from the nanoparticle groups
(Figure 1B,C) and moderate infiltration in
those from the LPS group (Figure 1D).
Treatment with LPS + 14-nm nanoparticles
markedly enhanced neutrophil sequestration
into the lung parenchyma compared with LPS
alone (Figure 1E), whereas LPS + 56-nm
nanoparticles did not (Figure 1F). Further-
more, we performed morphometric analysis to
quantitate the number of neutrophils in the
lung (Table 2). Although the number of inﬁl-
trated neutrophils in the lung parenchyma was
greater in the nanoparticle groups than in the
vehicle group, it did not reach signiﬁcant dif-
ference. Compared with vehicle challenge, the
LPS challenge signiﬁcantly increased the num-
ber of neutrophils (p < 0.01). The LPS +
14-nm nanoparticle group showed a signifi-
cantly increased number of neutrophils com-
pared with the LPS group or the 14-nm
nanoparticle group (p < 0.01). LPS + 56-nm
nanoparticle group revealed increases in the
number compared with the 56-nm nanoparti-
cle group (p < 0.01) but was not signiﬁcantly
different from the LPS group.
Effects of nanoparticles on the expression
of proinflammatory cytokine proteins in the
lung. To investigate local cytokine expression
related to LPS, we measured protein levels of
IL-1β and TNF-α in lung tissue supernatants
24 hr after intratracheal instillation (Table 3).
LPS challenge signiﬁcantly elevated the levels
of IL-1β compared with vehicle challenge
(p < 0.01). The level was signiﬁcantly greater
in the LPS + 14-nm nanoparticle group than
in the LPS or the 14-nm nanoparticle group
(p < 0.01). The level was greater in the
LPS + 56-nm nanoparticle group than in the
56-nm nanoparticle group (p < 0.01). The
level of TNF-α was not significantly altered
among the experimental groups.
Effects of nanoparticles on the expression
of chemokine proteins in the lung. To explore
local chemokine expression related to LPS, we
measured protein levels of MIP-1α, MIP-2,
MCP-1, and KC in lung tissue supernatants
24 hr after intratracheal instillation (Table 4).
Challenge with 14-nm nanoparticles alone
elevated the levels of all these chemokines com-
pared with vehicle challenge but without sig-
nificance except for KC (p < 0.05). LPS
exposure signiﬁcantly increased the levels of all
the chemokines compared with vehicle expo-
sure (p < 0.01). The levels were significantly
greater in the LPS + 14-nm nanoparticle group
than in the LPS group or the 14-nm nanopar-
ticle group (p < 0.01). The level was signifi-
cantly greater in the LPS + 56-nm nanoparticle
group than in the 56-nm nanoparticle group
(p < 0.01).
Effects of nanoparticles on formations of
8-OHdG in the lung. To investigate the con-
tribution of oxidative stress, we next studied
8-OHdG formation in the lung specimens by
immunohistochemistry 24 hr after intratra-
cheal instillation (Figure 2). In the vehicle
group, positive staining for 8-OHdG was
barely detectable (Figure 2A). Nanoparticle
Nanoparticles and lung inflammation
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Table 2. Quantitative analysis for neutrophil sequestration into the lung and immunohistochemistry (mean
± SE) after intratracheal challenge.
Treatment Neutrophils (cell number/HPF) 8-OHdG (immunohistochemical score)
Vehicle 3.75 ± 1.34 0.63 ± 0.13
14-nm nanoparticles 8.35 ± 1.24 1.88 ± 0.34
56-nm nanoparticles 7.30 ± 1.90 1.87 ± 0.24
LPS 67.5 ± 9.30** 1.25 ± 0.14
LPS + 14-nm nanoparticles 153.6 ± 11.2**,##,†† 2.88 ± 0.47**,#
LPS + 56-nm nanoparticles 75.9 ± 12.6**,†† 2.25 ± 0.32*
*p < 0.05 versus the vehicle group. **p < 0.01 versus the vehicle group. #p < 0.05 versus the LPS group. ##p < 0.01 versus
the LPS group. ††p < 0.01 versus the nanoparticle group.
Table 3. Protein levels of cytokines in the lung tissue supernatants (mean ± SE) after intratracheal challenge.
Treatment IL-1β (ng/total lung supernatants) TNF-α (pg/total lung supernatants)
Vehicle 0.3 ± 0.2 704.3 ± 48.3
14-nm nanoparticles 6.1 ± 3.0 665.0 ± 45.0
56-nm nanoparticles 3.7 ± 1.6 649.6 ± 44.8
LPS 39.4 ± 4.4 ** 655.0 ± 18.4
LPS + 14-nm nanoparticles 67.7 ± 11.1 **,## ,†† 658.4 ± 37.3
LPS + 56-nm nanoparticles 40.4 ± 10.6 **,†† 693.8 ± 38.2
**p < 0.01 versus the vehicle group. ##p < 0.01 versus the LPS group. ††p < 0.01 versus the nanoparticle group.
Table 4. Protein levels of chemokines (pg/total lung supernatants; mean ± SE) in the lung tissue super-
natants after intratracheal challenge.
Treatment MIP-1α MIP-2 MCP-1 KC
Vehicle 12.0 ± 8.0 28.5 ± 7.9 51.1 ± 23.4 14.7 ± 10.1
14-nm nanoparticles 303.4 ± 135.9 232.7 ± 135.3 546.8 ± 161.3 817.1 ± 268.5*
56-nm nanoparticles 171.1 ± 56.1 108.6 ± 52.2 226.1 ± 68.6 344.3 ± 179.9
LPS 1941.9 ± 213.7** 1723.3 ± 205.1** 2201.0 ± 222.6** 3507.4 ± 197.2**
LPS + 14-nm nanoparticles 4131.5 ± 758.9**,##,†† 3150.2 ± 340.6**,##,†† 4203.2 ± 494.5**,##,†† 5847.0 ± 317.0**,##,††
LPS + 56-nm nanoparticles 2281.2 ± 642.7**,†† 1554.3 ± 402.1**,†† 2327.0 ± 397.4**,†† 3207.7 ± 469.6**,††
*p < 0.05 versus the vehicle group. **p < 0.01 versus the vehicle group. ##p < 0.01 versus the LPS group. ††p < 0.01 versus
the nanoparticle group.
Figure 1. Histopathologic ﬁndings of the lung 24 hr after intratracheal administration of vehicle (A), two sizes
of carbon black nanoparticles (14 nm, B; 56 nm, C; 4 mg/kg), LPS (2.5 mg/kg; D), or LPS + nanoparticles
(14 nm, E; 56 nm, F). Lung histology was assessed by H&E stain; n = 5 per group. See “Materials and
Methods” for details.
Vehicle 14-nm nanoparticles 56-nm nanoparticles
LPS + 56-nm nanoparticles LPS + 14-nm nanoparticles LPS
A B C
D E Fchallenge induced moderate staining for
8-OHdG (Figure 2B,C). LPS challenge also
induced moderate staining (Figure 2D). On
the other hand, LPS plus nanoparticles resulted
in intensive expression of immunoreactive
8-OHdG compared with LPS or nanoparticles
alone (Figure 2E,F). The extent and intensity
of the expression were strongest in the
LPS + 14-nm nanoparticle group. We per-
formed morphometric analysis to quantitate
the extent and intensity of immunoreactive
8-OHdG among the experimental groups
(Table 2). Compared with vehicle treatment,
nanoparticle or LPS treatment revealed
increased immunoreactivity for -OHdG (not
signiﬁcant). The immunohistochemical score
with extent and intensity was greater in the
nanoparticle groups than in the LPS group,
although it did not show significance.
However, the score was greater in the LPS plus
nanoparticle groups than in the vehicle group
(p < 0.01 for the LPS + 14-nm nanoparticle
group, p < 0.05 for the LPS + 56-nm nanopar-
ticle group) or the LPS group (p < 0.05 for the
LPS + 14-nm nanoparticle group, not signiﬁ-
cant for the LPS + 56-nm nanoparticle group).
Effects of nanoparticles on coagulatory
changes. To investigate the impact of airway
exposure to nanoparticles on the coagulatory
system, we analyzed coagulatory parameters
24 hr after intratracheal challenge (Table 5).
PT was not signiﬁcantly different among the
experimental groups. LPS challenge with or
without nanoparticles caused prolongation of
APTT compared with vehicle challenge
(p < 0.05). APTT was further prolonged in
the LPS plus nanoparticle groups compared
with the LPS group, but it did not achieve
statistical significance. The fibrinogen level
was signiﬁcantly elevated after LPS challenge
(p < 0.01 vs. vehicle). The level was higher in
the LPS plus nanoparticle groups than in the
LPS group (p < 0.01 for the LPS + 14-nm
nanoparticle group, not significant for the
LPS + 56-nm nanoparticle group) or the
nanoparticle groups (p < 0.01). LPS signifi-
cantly decreased APC compared with vehicle
(p < 0.05). The activity was further decreased
in the LPS plus nanoparticle groups com-
pared with the LPS group (not signiﬁcant) or
the nanoparticle groups (p < 0.05). Compared
with the vehicle group, LPS showed a signiﬁ-
cant increase in the level of vWF (p < 0.05).
The level was greater in the LPS + 14-nm
nanoparticle group than in the LPS group
(not significant) or the 14-nm nanoparticle
group (p < 0.01).
Discussion
The present study has demonstrated that
14-nm carbon black nanoparticles instilled
intratracheally markedly enhance neutrophilic
lung inflammation with pulmonary edema
related to bacterial endotoxin, and 56-nm
nanoparticles show fewer effects than 14-nm
nanoparticles. The enhancement is paralleled
by the increased local expression levels of
proinﬂammatory cytokine such as IL-1β and
chemokines such as MIP-1α, MIP-2, MCP-1,
and KC. TNF-α levels were not affected by
any of the treatments. In addition, combined
challenge with LPS and 14-nm nanoparticles
significantly increases circulatory fibrinogen
level compared with challenge with LPS alone.
Epidemiologic studies have implicated the
causal correlation between atmospheric con-
centration of PM2.5 and cardiopulmonary
adverse effects (Brook et al. 2004; Peters et al.
1997; Samet et al. 2000). Among con-
stituents involved in PM2.5, DEPs are impor-
tant for their apparent toxicity (Morgan et al.
1997; Pandya et al. 2002). In fact, we have
experimentally demonstrated that DEPs
enhance antigen-related airway inﬂammation
(Takano et al. 1997) and lung inﬂammation
related to bacterial endotoxin (Takano et al.
2002) in vivo. DEPs are small particles with
carbonaceous cores (Schuetzle 1983). Recently,
we have demonstrated that carbon nano-
particles of the same sizes as those used in the
present study facilitate antigen-related airway
inﬂammation in mice (Inoue et al. 2005a). It
is noteworthy that 14-nm nanoparticles pre-
dominantly enhance allergic airway inﬂamma-
tion, including lung expression of cytokines
and chemokines related to antigen and
immunoglobuin production, compared with
56-nm nanoparticles (Inoue et al. 2005a). On
the other hand, we have previously shown that
intratracheal instillation with DEPs (8 mg/kg;
Takano et al. 2002) or the residual carbona-
ceous cores of DEPs after extraction with
dichloromethane (washed DEPs, 4 mg/kg;
Yanagisawa et al. 2003) worsens lung inﬂam-
mation related to LPS in the same protocol as
the present study. In the present study, 14-nm
nanoparticles markedly aggravated lung
inflammation related to bacterial endotoxin,
which was conﬁrmed by the counts of inﬁltra-
tion of inflammatory leukocytes in the BAL
ﬂuid and by the histologic assessment. On the
other hand, 56-nm nanoparticles did not sig-
nificantly exacerbate the inflammation. Our
present study a) expands the understanding of
the effects of environmental particles on bacte-
rial-endotoxin–related lung inflammation
in vivo and b) indicates that smaller (14 nm)
particles can predominantly exaggerate bacter-
ial endotoxin-related lung inﬂammation com-
pared with larger (56 nm) particles, as well as
allergic types of inﬂammation.
Our results apparently indicate that 14-nm
nanoparticles can aggravate LPS-related lung
inﬂammation more than 56-nm particles when
the weight of particles is equal. Based on our
previous studies using DEPs (Takano et al.
2002; Yanagisawa et al. 2003), we chose a
dosage of 4 µg/kg of the particles. In contrast,
however, it is important to note the surface
area of the nanoparticles used in this study.
Inoue et al.
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Figure 2. Immunohistologic staining for 8-OHdG in the lung 24 hr after intratracheal administration of vehi-
cle (A), two sizes of carbon black nanoparticles (14 nm, B; 56 nm, C; 4 mg/kg), LPS (2.5 mg/kg; D), or LPS +
nanoparticles (14 nm, E; 56 nm, F); n = 5 per group. See “Materials and Methods” for details.
Vehicle 14-nm nanoparticles 56-nm nanoparticles
LPS + 56-nm nanoparticles LPS + 14-nm nanoparticles LPS
A B C
D E F
Table 5. Plasma coagulatory parameters after intratracheal instillation.
Treatment PT (sec) APTT (sec) Fibrinogen (mg/dL) APC (%) vWF (%)
Vehicle 11.0 ± 0.2 26.9 ± 0.8 361.2 ± 34.1 4.3 ± 0.1 74.2 ± 3.2
14-nm nanoparticles 11.1 ± 0.1 27.7 ± 1.2 415.9 ± 16.8 3.8 ± 0.3 77.9 ± 5.1
56-nm nanoparticles 10.7 ± 0.2 26.9 ± 0.8 383.3 ± 21.9 4.3 ± 0.2 68.2 ± 3.9
LPS 10.9 ± 0.2 30.4 ± 0.4*,† 640.5 ± 24.6** 2.7 ± 0.1* 100.5 ± 6.3*
LPS + 14-nm nanoparticles 11.1 ± 0.1 31.2 ± 0.5*,† 735.9 ± 28.9**,##,†† 2.6 ± 0.2*,† 112.7 ± 1.9**,††
LPS + 56-nm nanoparticles 11.2 ± 0.1 32.2 ± 0.7*,† 689.3 ± 26.4**,†† 2.3 ± 0.2*,† 85.2 ± 4.6
*p < 0.05 versus the vehicle group. **p < 0.01 versus the vehicle group. ##p < 0.01 versus the LPS group. †p < 0.05 versus
the nanoparticle group. ††p < 0.01 versus the nanoparticle group.The surface area of particles reportedly corre-
lates with lung inflammation (Duffin et al.
2002). In our study, the surface area of the
14-nm nanoparticles was 6.7-fold larger than
that of 56-nm nanoparticles (300 m2/g vs.
45 m2/g). Alternatively, our study has demon-
strated not only the size effects of nanoparticles
on acute lung inﬂammation but also the effects
of their surface area and/or the effects of their
number on inﬂammation. Unfortunately, we
could not examine the effects of the nano-
particles with the same particle number in the
present study. The number of smaller nano-
particles is larger than that of larger nano-
particles per unit mass. Future inhalation
studies should provide better understanding of
the effects of the nanoparticles on acute lung
inflammation by using uniform surface area
and particle numbers.
The mechanisms underlying the enhancing
effects of 14-nm nanoparticles on lung inﬂam-
mation remain unexplored. Pathogenesis of
acute lung inflammation reportedly involves
ampliﬁed lung expression of proinﬂammatory
cytokines such as IL-1β and TNF-α and
chemokines such as IL-8, MIP-1α, and
MCP-1 (Martin 1999; Puneet et al. 2005;
Standiford et al. 1995). In our previous work,
indeed, we have conﬁrmed the lung expression
of proinﬂammatory cytokines and chemokines,
including IL-1β, MIP-1α, MCP-1, and KC,
in the lung 24 hr after intratracheal administra-
tion of LPS, DEPs, or washed DEPs, which is
concomitant with the abrogated lung injuries
(Takano et al. 2002; Yanagisawa et al. 2003).
In the present study, as well as in our previous
studies, exaggerating effects of nanoparticles on
lung inﬂammation should be mediated, at least
in part, through the enhanced lung expression
of IL-1β, MIP-1α, MCP-1, MIP-2, and KC.
In the present study, TNF-α was not signiﬁ-
cantly different among the experimental
groups. TNF-α reportedly reaches peaks 1 hr
after LPS injection (Heremans et al. 2000);
this might be due to the kinetics of the
response, in which this cytokine may peak
much earlier and may return to normal values
within 24 hr. The LPS dose we used here and
in our previous studies (Takano et al. 2002;
Yanagisawa et al. 2003) is high, including a
92% neutrophilic response in the BAL ﬂuid in
the present study. Alternatively, this high dose
response of maximal neutrophilic inﬂux may
be responsible for the phenomenon.
Environmental particles including DEPs
cause oxidative stress, leading to aggravated
tissue injury (Lim et al. 1998). Nanoparticle
exposure also causes oxidative stress in the
lung (Nel 2005). Enhanced formation of
8-OHdG is a marker of oxidative stress and
has been reported in the lung exposed to
DEPs (Arimoto et al. 1999; Sanbongi et al.
2003). Further, we have recently demon-
strated its enhanced formation in the murine
lung exposed to LPS (Inoue et al. 2005b). In
the present study, immunoreactive 8-OHdG
in the lung was greater in the LPS + nanopar-
ticle groups than in the LPS group. These
results indicate that exaggerated lung injury
by nanoparticles may be mediated, in part, via
the enhanced oxidative stress. Interestingly,
however, the nanoparticle groups showed
more intense immunoreactive 8-OHdG than
did the LPS group or the vehicle group.
Alternatively, airway exposure to nanoparti-
cles may cause oxidative stress in the lung
independent of LPS exposure. This notion is
supported by results of our recent study in
which nanoparticles enhanced 8-OHdG for-
mation in the lung in the presence or absence
of antigen (Inoue et al. 2005a).
Although the effects of nanoparticles alone
were mostly nonsignificant, the data suggest
that they are certainly not negligible, in
particular, for pulmonary edema. In contrast,
the response to 14-nm nanoparticles + LPS was
almost greater than the sum of the individual
responses, but that to 56-nm nanoparticles
+ LPS was not. Thus, these observations could
be considered to reflect synergistic effects of
two inflammation-inducing agents such as
14-nm nanoparticles and LPS and as additive
effects such as 56-nm nanoparticles and LPS.
Nanoparticles are able to penetrate deeply
into the respiratory tract and can even pass
through the lung to reach systemic circulation
(MacNee and Donaldson 2000; Nemmar
et al. 2001). Nemmar et al. (2001) have pre-
viously demonstrated that nanoparticles can
migrate into circulation. In the present study,
the LPS plus nanoparticle groups, speciﬁcally
the LPS + 14-nm nanoparticle group, showed
significantly higher fibrinogen levels com-
pared with the LPS group. Additionally,
although statistical significance was not
achieved, enhanced activity of vWF induced
by LPS was further increased by its combina-
tion with 14-nm nanoparticles. These find-
ings suggest that smaller nanoparticles can
facilitate coagulatory disturbance accompa-
nied by lung inﬂammation. Enhancing effects
of 14-nm nanoparticles on LPS-elicited pul-
monary edema can further support this con-
cept. Interestingly, exposure to nanoparticles
alone did not induce significant fibrinogen
production/release or activate vWF. It might
be hypothesized that endothelial-epithelial
damage induced by LPS and subsequent
infiltrated effector leukocytes allow large
amounts of smaller nanoparticles to pass eas-
ily into circulation, resulting in synergistic
effects on hemostasis, including coagulatory
disturbance. On the other hand, exposure to
environmental particles reportedly generates
local and systemic oxidative stress, which in
turn induces/enhances inflammation and
blood coagulation (MacNee and Donaldson
2000). Further, Nemmar et al. (2001) have
demonstrated that nanoparticles instilled
intratracheally rapidly diffuse from the lung
into the systemic circulation in vivo. Therefore,
it is also possible that intratracheally instilled
nanoparticles enter the circulation by them-
selves and contribute to high susceptibility
against LPS-elicited systemic inﬂammation and
coagulatory disturbance. Future studies are
needed to confirm the penetration and to
address the above-mentioned hypothesis.
In the real world PM contains endotoxins;
therefore, we simultaneously inhale endotoxins
and PM in ambient air. In other words, we are
involuntary primed by endotoxins. In addi-
tion, for the extrapolation to the human situa-
tion, it would be of interest to know whether
an already existing and earlier-induced inﬂam-
mation can be exacerbated by exposure to
nanoparticles. Therefore, studies elucidating
the effects of nanoparticles on LPS-priming
and/or LPS-infected models may also provide
better understanding of PM toxicology.
Finally, it can be hypothesized that LPS
molecules physically adhere to the surface of
nanoparticles and thus achieve concentrations
in a microenvironment that enhance their
proinflammatory potency. To examine the
hypothesis, we centrifuged each solution from
the LPS group or the two LPS plus nano-
particle groups and measured the LPS levels
in the supernatants by LPS-specific Limulus
amebocyte lysate assay. The LPS levels were
nearly equal in the two groups (conducted as
three independent experiments; data not
shown). Thus, it is not likely that LPS adheres
to nanoparticles in the present study.
In conclusion, this study has highlighted
that nanoparticles enhance lung inﬂammation
related to bacterial endotoxin. The enhance-
ment is mediated through the increased local
expression of IL-1β and chemokines. The
enhancing effects are more prominent with
14-nm nanoparticles than with 56-nm
nanoparticles in overall trend. Fourteen-
nanometer nanoparticles also enhance coagula-
tory disturbance accompanied by lung
inflammation. These results suggest that
nanoparticles can exacerbate lung inﬂammation
related to bacterial endotoxin and subsequent
coagulatory disturbance. The aggravating effect
is larger with the smaller particles.
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